Duloxetine-induced cutaneous adverse reaction [3]

Journal of Clinical Psychopharmacology

Volumn 28, Issue 1, 2008, Pages 104-105

  Oulis, Panagiotis ^a   Masdrakis, Vasilios G ^a   Karakatsanis, Nikolaos A ^a   Karapoulios, Evangelos ^a   Kouzoupis, Anastasios V ^a   Soldatos, Constantin R ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; MIRTAZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HOARSENESS; HUMAN; LETTER; MAJOR DEPRESSION; PERIORBITAL EDEMA; PRIORITY JOURNAL; PRURITUS; RASH; SKIN TOXICITY; SYMPTOMATOLOGY; TONGUE SWELLING;

ADRENERGIC UPTAKE INHIBITORS; DEPRESSIVE DISORDER, MAJOR; EXANTHEMA; FEMALE; HUMANS; MIDDLE AGED; PRURITUS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 38349102453     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e318160863e     Document Type: Letter

References (6)

1. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004;37(suppl 1):S39-S45.
2. Tan EK, Grattan CE. Drug induced urticaria. Expert Opin Drug Saf. 2004;3:471-484.
3. Krasowska D, Szymanek M, Schwartz RA, et al. Cutaneous effects of the most commonly used antidepressant indication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol. 2007;56:848-853.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
5. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2003;20:327-341.
6. Mallinckrodt CH, Prakash A, Andorn AC, et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res. 2006;40:337-348.